The use of P2Y12 inhibitors was similar between male and female patients, and in both cases, it reduced the risk of major cardiovascular events, myocardial infarction, and stent thrombosis. The study also found that the use of P2Y12 inhibitors had a similar increased risk of bleeding complications in both sexes. The gene discussed is P2RY12; the disease is myocardial infarction.